source
- Braveheart Bio's Hengrui-licensed cardiac therapy shows positive mid-stage trial resultsBraveheart Bio announced that its heart muscle therapy, licensed from Jiangsu Hengrui Pharmaceuticals, has achieved a positive outcome in a Phase 2 trial. The mid-stage study met its primary endpo…
- Biotech layoffs slow as companies like BioNTech cut nearly 1,900 jobs amid market pressuresThe biotech sector has seen more than 40 layoff announcements through the end of April 2026, a decline from the over 50 rounds reported in the final months of 2025. Analysts had expected the pace t…